Telangiectasia macularis eruptiva perstans treated with narrow-band UVB phototherapy and heliotherapy during the COVID-19 pandemic
doi.org/10.47895/amp.v56i13.4543
- Author:
Christine E. de Guia, MD
1
;
Alma Gay Concepcion T. Amado, MD
1
Author Information
1. Rizal Medical Center, Pasig City, Philippines
- Publication Type:Case Reports
- Keywords:
telangiectasia macularis eruptiva perstans
- MeSH:
mastocytosis;
phototherapy;
heliotherapy
- From:
Acta Medica Philippina
2023;57(7):64-66
- CountryPhilippines
- Language:English
-
Abstract:
Telangiectasia macularis eruptiva perstans (TMEP) is a rare disease, previously classified as a variant of cutaneous mastocytosis. While no gold standard of treatment exists, several treatments have been studied. We report a case of a 63-year-old woman who presented with long-standing asymptomatic telangiectatic macules beginning on the upper chest, back, and bilateral arms, with occasional pruritus and no other systemic symptoms. Skin biopsy, along with Giemsa stain, revealed findings consistent with TMEP. The patient underwent testing for serum tryptase level, which was within normal limits. The patient was started on topical steroids for two weeks and antihistamine therapy, with a noted decrease in pruritus but no change in cutaneous lesions. She was then advised to start phototherapy, and subsequently underwent a total of five sessions of narrow-band ultraviolet B phototherapy, after which she noted lightening of the lesions. Due to the COVID pandemic, the patient was shifted to heliotherapy with continued lightening of lesions after two months of thrice weekly sessions. This rare case is supportive of narrow-band ultraviolet B phototherapy and heliotherapy as promising treatment options for cases of TMEP.
- Full text:4543-Article Text-115648-1-10-20230726.pdf
